Harvard Bioscience, Inc. vs Nephros, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Harvard Bioscience, Inc. is the larger company by market value: $38 M against $36 M for Nephros, Inc., 1.1 times as much (market caps of Oct 26, 2026 for Harvard Bioscience, Inc. and Oct 30, 2026 for Nephros, Inc.).
- Harvard Bioscience, Inc. had more revenue: $87 M against $19 M for Nephros, Inc., both in the year to December 2025.
- Nephros, Inc. made a net profit of $1 M, while Harvard Bioscience, Inc. made a net loss of $57 M.
- Nephros, Inc. keeps more of each dollar of sales: a net margin of 6.3% against -65.5% for Harvard Bioscience, Inc.
- Nephros, Inc.'s revenue grew faster in its latest fiscal year: +32.7% against -8.1% for Harvard Bioscience, Inc.
- Both are in the distress zone of the Altman Z-score.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Harvard Bioscience, Inc. HBIO · #22,291 in the world | Nephros, Inc. NEPH · #22,480 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments | Medical Instruments |
| Founded | 1901 | — |
| Size | ||
| Market cap | $38 M | $36 M |
| Revenue | $87 M | $19 M |
| Net income | $-57 M | $1 M▲ best |
| Employees | — | 36 |
| Valuation | ||
| P/E ratio | — | 18.7× |
| Price to sales | 0.4× | 1.6× |
| Price to book | 2.7× | 3.5× |
| Free cash flow yield | 14.5%▲ best | -1.6% |
| Profitability | ||
| Gross margin | 57.7% | 61.8%▲ best |
| Operating margin | -56.1% | 6.1%▲ best |
| Net margin | -65.5% | 6.3%▲ best |
| Return on equity | -147.1% | 12.7%▲ best |
| Growth | ||
| Revenue growth | -8.1% | 32.7%▲ best |
| Revenue growth, 3 years a year | -8.6% | 23.5%▲ best |
| Earnings per share growth | — | 1000.0% |
| Financial strength | ||
| Debt to equity | 2.6× | — |
| Interest cover | -37.4× | — |
| Cash | ||
| Free cash flow margin | 6.3% | — |
| Strength scores | ||
| Piotroski F-score | 5 of 9 | — |
| Altman Z-score zone | distress | distress |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Harvard Bioscience, Inc. or Nephros, Inc.?
Harvard Bioscience, Inc. is the larger company by market value: $38 M against $36 M for Nephros, Inc., 1.1 times as much (market caps of Oct 26, 2026 for Harvard Bioscience, Inc. and Oct 30, 2026 for Nephros, Inc.).
Which makes more money, Harvard Bioscience, Inc. or Nephros, Inc.?
Harvard Bioscience, Inc. had more revenue: $87 M against $19 M for Nephros, Inc., both in the year to December 2025. Nephros, Inc. made a net profit of $1 M, while Harvard Bioscience, Inc. made a net loss of $57 M.
Which is more profitable, Harvard Bioscience, Inc. or Nephros, Inc.?
Nephros, Inc. keeps more of each dollar of sales: a net margin of 6.3% against -65.5% for Harvard Bioscience, Inc.
Which is growing faster, Harvard Bioscience, Inc. or Nephros, Inc.?
Nephros, Inc.'s revenue grew faster in its latest fiscal year: +32.7% against -8.1% for Harvard Bioscience, Inc.
Which is financially stronger, Harvard Bioscience, Inc. or Nephros, Inc.?
Both are in the distress zone of the Altman Z-score.
More about Harvard Bioscience, Inc.
More about Nephros, Inc.
Sources#
Every figure on this page comes from these, with the date shown next to it.